Evidence map›Paper›PMID 36863449›Full record

ArticleThe Journal of investigative dermatology2023

Blockade of the Immune Checkpoint CD47 by TTI-621 Potentiates the Response to Anti-PD-L1 in Cutaneous T-Cell Lymphoma.

Zhen Han, Xiwei Wu, Hanjun Qin, Yate-Ching Yuan, Jasmine Zain, D Lynne Smith, Oleg E Akilov, Steven T Rosen, Mingye Feng, Christiane Querfeld

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of investigative dermatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Zhen HanDivision of Dermatology, Department of Surgery, City of Hope, Duarte, California, USA; Beckman Research Institute, City of Hope, Duarte, California, USA.
Xiwei WuBeckman Research Institute, City of Hope, Duarte, California, USA; Integrative Genomics and Bioinformatics, City of Hope, Duarte, California, USA; Computational and Quantitative Medicine, City of Hope, Duarte, California, USA.
Hanjun QinBeckman Research Institute, City of Hope, Duarte, California, USA; Integrative Genomics and Bioinformatics, City of Hope, Duarte, California, USA.
Yate-Ching YuanBeckman Research Institute, City of Hope, Duarte, California, USA; Computational and Quantitative Medicine, City of Hope, Duarte, California, USA; Translational Bioinformatics, Center for informatics, City of Hope, Duarte, California, USA.
Jasmine ZainDepartment of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA.
D Lynne SmithDepartment of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA.
Oleg E AkilovCutaneous Lymphoma Program, Department of Dermatology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Steven T RosenBeckman Research Institute, City of Hope, Duarte, California, USA; Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA.
Mingye FengBeckman Research Institute, City of Hope, Duarte, California, USA; Department of Immuno-Oncology, City of Hope, Duarte, California, USA.
Christiane QuerfeldDivision of Dermatology, Department of Surgery, City of Hope, Duarte, California, USA; Beckman Research Institute, City of Hope, Duarte, California, USA; Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA; Department of Pathology, City of Hope, Duarte, California, USA. Electronic address: cquerfeld@coh.org.
City Of Hope National Medical Center · USCity of Hope · USUniversity of Pittsburgh Medical Center · US

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI XIWEI WU · 1985 to 2026
$86.3M
Cutaneous T cell lymphoma: a paradigm for dissecting susceptibility and resistance to checkpoint inhibition therapyR01CA229510 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI QUERFELD, CHRISTIANE · 2019 to 2023
$2.8M
Identifying and engaging a universal adjuvant for breaking macrophage immune tolerance in cancerR01CA255250 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI FENG, MINGYE · 2021 to 2025
$2.1M
NCI NIH HHS P30 CA033572NCI NIH HHS R01 CA229510NCI NIH HHS R01 CA255250
6 · The paper itself

Abstract

Cutaneous T-cell lymphoma (CTCL) is an incurable and cosmetically disfiguring disease associated with microenvironmental signals. We investigated the effects of CD47 and PD-L1 immune checkpoint blockades, as a strategy for targeting both innate and adaptive immunity. CIBERSORT analysis identified the immune-cell composition in the CTCL tumor microenvironment and the immune checkpoint expression profile for each immune-cell gene cluster from CTCL lesions. We investigated the relationship between MYC and CD47 and PD-L1 expression and found that MYC short hairpin RNA knockdown and MYC functional suppression by TTI-621 (SIRPαFc) and anti-PD-L1 (durvalumab) in CTCL cell lines reduced the expression of CD47 and PDL1 mRNA and protein as measured by qPCR and flow cytometry, respectively. In vitro, blockade of the CD47-SIRPα interaction with TTI-621 increased the phagocytic activity of macrophages against CTCL cells and enhanced CD8

Indexed as

Lymphoma, T-Cell, CutaneousNeoplasmsSkin NeoplasmsB7-H1 AntigenCD47 AntigenHumansImmunoglobulin GImmunotherapyTumor MicroenvironmentB7-H1 AntigenCD47 AntigenCD47 protein, humanImmunoglobulin GTTI-621

Identifiers

PMID36863449
PMCPMC10363206
OpenAlexW4322621543

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.